Affiliation:
1. Military Medical Academy named after S.M. Kirov (Branch) of the Ministry of Defense of Russia
2. Central Military Clinical Hospital named after P.V. Mandryka of the Ministry of Defense of Russia
3. Military Medical Academy named after S.M. Kirov of the Ministry of Defense of Russia
Abstract
The concept of high-risk pulmonary artery embolism determines that verification of the occlusion of the pulmonary arterial bed requires urgent restoration of pulmonary blood flow in such patients. Thrombolytic therapy is currently recognized as the main treatment for pulmonary artery thromboembolism. It can save patients’ lives, prevent the development of chronic post embolic pulmonary hypertension and thromboembolism recurrence. The literature review presents thrombolytic medications used in the treatment of pulmonary thromboembolism, describes indications for thrombolytic therapy, comparative efficiency and safety of various thrombolytics. The main complications of thrombolytic therapy are described and the issues of increasing its safety are raised. Criteria for the success of thrombolysis are early diagnosis, accurate risk stratification, and adequate use of reperfusion agents in patients with high-risk or transitionally high-risk of pulmonary embolism.
Publisher
Medical Informational Agency Publishers
Reference70 articles.
1. Bokeria L.A., Zatevakhin I.I., Kirienko A.I. et al. Russian clinical recommendations on diagnosis, treatment, prevention of venous thromboembolic complications. Flebology. 2015;9(4/2):4–46. (in Russian)
2. Konstantinides S.V., Meyer G., Becattini С. et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC), Eur. Heart J. 2020;41(4):543–603. https://DOI.org/10.1093/eurheartj/ehz405
3. Martinez C., Cohen A.T., Bamber L., Rietbrock S. Epidemiology of first and recurrent venous thromboembolism: a population-based cohort study in patients without active cancer. Thromb. Haemost. 2014;112(2):255–263.
4. Wong P., Baglin T. Epidemiology, risk factors and sequelae of venous thromboembolism. Phlebology. 2012;27(2–11).
5. Boytsov S.A., Deev A.D., Shalnova S.A. Mortality and Risk Factors of Noncommunicable Diseases in Russia: Features, Dynamics, Prognosis. Therapeutic Archive. 2017;89(1):5–13. (in Russian)